Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy.
Ontology highlight
ABSTRACT: In the absence of cell surface cancer-specific antigens, immunotherapies such as chimeric antigen receptor (CAR) T cells, monoclonal antibodies, or bispecific T cell engagers typically target lineage antigens. Currently, such immunotherapies are individually designed and tested for each disease. This approach is inefficient and limited to a few lineage antigens for which the on-target/off-tumor toxicities are clinically tolerated. Here, we sought to develop a universal CAR T cell therapy for blood cancers directed against the pan-leukocyte marker CD45. To protect healthy hematopoietic cells, including CAR T cells, from CD45-directed on-target/off-tumor toxicity while preserving the essential functions of CD45, we mapped the epitope on CD45 that is targeted by the CAR and used CRISPR adenin
SUBMITTER: Wellhausen N
PROVIDER: S-EPMC10682510 | biostudies-literature | 2023 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA